MedTrace Logo

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

NCT05346653 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-09-04

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to observe hemodynamic effects of initiating sodium-glucose co-transporter 2 inhibitors (SGLT2i) in patients admitted to the intensive care unit (ICU) with acute decompensated heart failure.

Conditions

  • Acute Decompensated Heart Failure

Interventions

DRUG

SGLT2i

dapagliflozin (10 mg daily)

OTHER

No SGLT2i

No SGLT2i

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Jonathan Grinstein, MD · University of Chicago

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2023-05-23
Completion
2023-05-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05346653 on ClinicalTrials.gov